Biocryst Pharmaceuticals

Angioedema drug’s upside puts BioCryst on path to profits in 2026

Posted by Jodi Leese Glusco | Feb 27, 2024

Sales of Orladeyo have jumped to $326 million last year from $133,000 in 2020. The company expects revenue from the drug of as much as $400 million this year.

Durham’s BioCryst strikes deal for treatment to combat vision loss linked to diabetes

Posted by WRAL TechWire | Nov 3, 2023

BioCryst Pharmaceuticals has struck a licensing deal with a Georgia based company for a treatment targeting vision loss among those suffering diabetic macular edema, or DME.

How women in biotech leadership are driving change in the workplace

Posted by Abbey Slattery | Sep 14, 2022

At BioCryst, women in leadership create a supportive community and ways to pave the trail for others.

Thoughtful analysis of market data and customer insights allows local biotech company to stay focused on the needs of patients

Posted by Abbey Slattery | Aug 10, 2022

Relentless, early and often data collection and insight generation allowed BioCryst to anticipate and strategically leverage information for the good of patients — a true competitive advantage and foundation for company success.

How a homegrown company maintains its culture through global expansion

Posted by Abbey Slattery | Jul 13, 2022

While BioCryst has been around for more than three decades, the past few years have brought unprecedented global growth for the biotech company.

How a local biotech company found its hybrid working environment “groove”

Posted by Abbey Slattery | Jun 22, 2022

Through listening to and incorporating employee feedback, BioCryst is creating the ideal hybrid work model — complete with a new office space here in the Triangle.